WHO Advisory Group Recommends Maftivimab for Clinical Trials in Bundibugyo Ebola Outbreak (rttnews.com)

• WHO Therapeutics Advisory Group recommends Maftivimab for clinical trials in Bundibugyo outbreak
• Maftivimab is the most potent component of Regeneron's Inmazeb cocktail
• Outbreak involves Bundibugyo ebolavirus in DRC and Uganda

"The WHO Therapeutics Advisory Group has recommended Regeneron's monoclonal antibody Maftivimab for prioritized evaluation in clinical trials targeting the ongoing Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda. Maftivimab is described as the most potent antibody component of Inmazeb, Regeneron's approved Ebola treatment. This recommendation aims to streamline testing of promising therapies during the current outbreak."